Trial Profile
An Open-Label, Multicenter Study to Evaluate Long-term Outcomes With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-II)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms TOPAZ II
- Sponsors AbbVie
- 27 May 2021 Status changed from active, no longer recruiting to completed.
- 15 Mar 2021 Planned End Date changed from 21 Mar 2021 to 12 May 2021.
- 15 Mar 2021 Planned primary completion date changed from 21 Mar 2021 to 12 May 2021.